pharma · Relapsed/Refractory Diffuse Large B-cell Lymphoma · Non-muscle invasive bladder cancer (NMIBC)
Shanghai Antengene Corporation
Shanghai Antengene Corporation Limited
Shanghai Antengene Corporation is a pharma organization headquartered in SAINT-LAURENT, CN. Primary therapeutic focus areas include Relapsed/Refractory Diffuse Large B-cell Lymphoma, Non-muscle invasive bladder cancer (N
SAINT-LAURENT, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- SAINT-LAURENT, CN
- Programs
- 3
- Drugs
- 8
- Patents
- 53
EG-70-101
Phase 2 · other · Non-muscle invasive bladder cancer (NMIBC)
EG-70-101 for Non-muscle invasive bladder cancer (NMIBC) is a Phase 2 program (other) at Shanghai Antengene Corporation Limited with 1 ClinicalTrials.gov record(s).
Internal code EG-70-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Antengene Corporation Limited
- Phase
- Phase 2
- Modality
- other
- Indication
- Non-muscle invasive bladder cancer (NMIBC)
- Status
- active
- Trials
- 1